Evidence map›Paper›PMID 37771410›Full record

ArticleJMIR AI

Artificial Intelligence-Enabled Software Prototype to Inform Opioid Pharmacovigilance From Electronic Health Records: Development and Usability Study.

Alfred Sorbello, Syed Arefinul Haque, Rashedul Hasan, Richard Jermyn, Ahmad Hussein, Alex Vega, Krzysztof Zembrzuski, Anna Ripple, Mitra Ahadpour

Abstract read
In one paragraph

Article in JMIR AI. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alfred SorbelloCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.
Syed Arefinul HaqueCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.
Rashedul HasanCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.
Richard JermynNeuromuscular Institute, Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ, United States.
Ahmad HusseinNeuromuscular Institute, Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ, United States.
Alex VegaNeuromuscular Institute, Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ, United States.
Krzysztof ZembrzuskiNeuromuscular Institute, Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ, United States.
Anna RippleLister Hill National Center for Biomedical Communications, National Library of Medicine-National Institutes of Health, Rockville, MD, United States.
Mitra AhadpourCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.

Funding

Intramural FDA HHS FD999999Intramural NIH HHS Z99 LM999999
6 · The paper itself

Abstract

Background: The use of patient health and treatment information captured in structured and unstructured formats in computerized electronic health record (EHR) repositories could potentially augment the detection of safety signals for drug products regulated by the US Food and Drug Administration (FDA). Natural language processing and other artificial intelligence (AI) techniques provide novel methodologies that could be leveraged to extract clinically useful information from EHR resources. Objective: Our aim is to develop a novel AI-enabled software prototype to identify adverse drug event (ADE) safety signals from free-text discharge summaries in EHRs to enhance opioid drug safety and research activities at the FDA. Methods: We developed a prototype for web-based software that leverages keyword and trigger-phrase searching with rule-based algorithms and deep learning to extract candidate ADEs for specific opioid drugs from discharge summaries in the Medical Information Mart for Intensive Care III (MIMIC III) database. The prototype uses MedSpacy components to identify relevant sections of discharge summaries and a pretrained natural language processing (NLP) model, Spark NLP for Healthcare, for named entity recognition. Fifteen FDA staff members provided feedback on the prototype's features and functionalities. Results: Using the prototype, we were able to identify known, labeled, opioid-related adverse drug reactions from text in EHRs. The AI-enabled model achieved accuracy, recall, precision, and Conclusions: The novel prototype uses innovative AI-based techniques to automate searching for, extracting, and analyzing clinically useful information captured in unstructured text in EHRs. It increases efficiency in harnessing real-world data for opioid drug safety and increases the usability of the data to support regulatory review while decreasing the manual research burden.

Indexed as

artificial intelligencedeep learningdrugEHRelectronic health recordsFood and Drug Administrationnatural languagepharmacovigilancereal world datasoftware application

Identifiers

PMID37771410
PMCPMC10538589

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.